Shots:
- The EC has approved Attrogy (diflunisal) to treat hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults with stage 1 or 2 polyneuropathy in all EEA states
- EC approval was based on a P-III trial showing that diflunisal significantly slowed disease progression in patients with TTR amyloidosis. At 24 mos. baseline, 1EP met diflunisal led to a mean NIS+7 increase of 8.2 points vs. 26.3 with PBO. 2EPs, including NIS, NIS-LL, Kumamoto score, and SF-36 physical score, also showed significant benefits vs PBO
- Diflunisal (250 mg BID), a difluorophenyl salicylic acid derivative, stabilizes the TTR tetramer
Ref: Purpose Pharma | Image: Purpose Pharma| Press Release
Related News:- Purpose Pharma’s Attrogy Receives the CHMP’s Positive Opinion for the Treatment of Hereditary Transthyretin-mediated Amyloidosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
